Retatrutide

Retatrutide is an investigational peptide therapeutic being developed for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). It is classified as a single-molecule multi-receptor agonist, or more specifically, a "tri-agonist."

Its mechanism of action involves the simultaneous activation of three distinct hormone receptors integral to metabolic control: the Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon (GCG) receptors. This approach combines the potent appetite suppression and glycemic control effects of GLP-1 and GIP agonism with the increased energy expenditure and enhanced fat metabolism associated with glucagon receptor activation. The therapeutic hypothesis is that targeting these three complementary pathways will produce a synergistic effect, leading to superior outcomes in weight reduction and metabolic health.

Retatrutide is in late-stage Phase 3 clinical trials as of June 2025. It has garnered significant scientific and public attention due to the unprecedented degree of weight loss and reduction in liver fat demonstrated in its Phase 2 clinical trials, with results that exceed those typically seen with single- or dual-agonist therapies.